tradingkey.logo
tradingkey.logo
Buscar

Daxor Corp

DXR
Añadir a la lista de seguimiento
10.380USD
+0.030+0.29%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
52.52MCap. mercado
29.85P/E TTM

Más Datos de Daxor Corp Compañía

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.

Información de Daxor Corp

Símbolo de cotizaciónDXR
Nombre de la empresaDaxor Corp
Fecha de salida a bolsaJul 25, 1983
Director ejecutivoFeldschuh (Michael Richard)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 25
DirecciónSuite 7120
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10118
Teléfono12122440555
Sitio Webhttps://www.daxor.com/
Símbolo de cotizaciónDXR
Fecha de salida a bolsaJul 25, 1983
Director ejecutivoFeldschuh (Michael Richard)

Ejecutivos de Daxor Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--
Mr. Bret Shapiro
Mr. Bret Shapiro
IR Contact Officer
IR Contact Officer
--
--
Mr. Caleb Desrosiers, Esq.
Mr. Caleb Desrosiers, Esq.
Independent Director
Independent Director
--
--
Mr. John Jefferies
Mr. John Jefferies
Chief Medical Officer
Chief Medical Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Richard Feldschuh
Mr. Michael Richard Feldschuh
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
213.69K
--
Mr. Jonathan Adam Feldschuh
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer, Director
Chief Scientific Officer, Director
53.91K
--
Mr. Robert J. (Bob) Michel
Mr. Robert J. (Bob) Michel
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
Chief Financial Officer, Chief Compliance Officer, Corporate Secretary
21.05K
--
Mr. Edward Feuer, CPA
Mr. Edward Feuer, CPA
Independent Director
Independent Director
1.00K
--
Dr. Henry D. Cremisi, M.D.
Dr. Henry D. Cremisi, M.D.
Independent Director
Independent Director
--
--
Ms. Joy Goudie, Esq.
Ms. Joy Goudie, Esq.
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Daxor Corp?

Los cinco principales accionistas de Daxor Corp son: Mr. Michael Richard Feldschuh

¿Cuántas instituciones poseen acciones de Daxor Corp (DXR)?

A fecha de 2026Q1, 16 instituciones poseen acciones de Daxor Corp, con un valor de mercado combinado de aproximadamente 120.43K, lo que representa el 2.07% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 11270.00.